Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. (Q36186934)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

author name string

Ahmad A Tarhini

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Joseph Stuckert

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sandra Lee

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Cindy Sander

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

John M Kirkwood

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

1 December 2008

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

27

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

38-44

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

A review of the S100 proteins in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Cancer statistics, 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Elevated serum levels of S100 and survival in metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

2 July 2018

Evaluation of new putative tumor markers for melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

2 July 2018

Analysis of survival by tumor response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

2 July 2018

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

S100 protein as tumoral marker in melanoma patients. Comparative study with sentinel node biopsy and whole body FDG-PET

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

Serum S100beta protein as a marker of disease activity in patients with malignant melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of Two Prognostic Markers for Malignant Melanoma: MIA and S100 β

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

On the release and half-life of S100B protein in the peripheral blood of melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

S100B protein detection in serum is a significant prognostic factor in metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of serum S-100B in malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of four different assays for determination of serum S-100B

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.17.1777

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36186934&oldid=1520459685"